Mode
Text Size
Log in / Sign up
N/A N=45 Treatment

Positive Processes and Transition to Health

Major Depressive Disorder · Post Traumatic Stress Disorder

Enrolled (actual)
45
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcome: Primary: Affective Updating Task (Pe et al., 2013; Pe, Raes, et al., 2013) — 0.54 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Positive Processes and Transition to Health (PATH) (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Case Western Reserve University
Primary completion
Jun 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Affective Updating Task (Pe et al., 2013; Pe, Raes, et al., 2013)
0.54
PRIMARY
Idiographic Behavioral Approach Task
25.65
PRIMARY
Probabilistic Reward Task (Pizzagalli et al., 2005)
-.03
SECONDARY
Posttraumatic Cognitions Inventory (Foa et al., 1999)
102.05
SECONDARY
Behavioral Activation for Depression Scale (Kanter et al., 2006)
106.5
SECONDARY
Snaith-Hamilton Pleasure Scale (Snaith et al., 1995)
21.79

Summary

The R61 will be an open trial to determine if Positive Processes and Transition to Health (PATH) engages the proposed targets: unproductive processing, avoidance, and reward deficits in a sample of 45 adults who have experienced a destabilizing life event involving profound loss or threat, report persistent stressor-related symptoms of PTSD and/or depression, and are elevated on symptoms related to 2 of the 3 therapeutic targets. Additionally, will examine whether patients perceive PATH as helpful and complete/adhere to treatment, and therapist fidelity. Patients will receive 6 sessions of PATH (with 2 boosters, if partial responders). Primary targets will be assessed at pre-treatment, week 4, post-treatment, and at 1- and 3-month follow-up; secondary targets at pre-treatment, weekly during treatment, post-treatment, and at 1- and 3-month follow-ups.

Eligibility Criteria

Inclusion Criteria

  • Destabilizing life event involving profound loss or threat, with a minimum duration of 12 weeks since the event, but occurred within the last 5 years.
  • Between the ages of 18 and 65.
  • Elevated target: Scores of at least moderate (1 or higher) on at least 2 of the 3 target mechanisms: re- experiencing or ruminative processing of the destabilizing event (PSS-I items: 1, 2, 3, 4 or QIDS-C item 11), avoidance (PSS-I items 6, 7, 8), or reward deficits (PSS-I items 12, 13, or QIDS-C item 13).

Exclusion Criteria

  • Current diagnosis of schizophrenia, delusional disorder, or organic mental disorder as defined by DSM-5.
  • Current diagnosis of bipolar disorder, depression with psychotic features, or depression severe enough to require immediate psychiatric treatment (i.e., serious suicide risk with intent and plan).
  • Severe self-injurious behavior or suicide attempt within the previous three months.
  • Unwilling or unable to discontinue current cognitive behavioral psychotherapy.
  • No clear memory of the destabilizing event or event occurred before age 3.
  • Unstable dose of psychotropic medications in prior 3 months.
  • Ongoing intimate relationship with the perpetrator (in assault related event).
  • Current diagnosis of a substance use disorder (DSM-5).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04678232). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search